Physician profile
Sherry Sood
NPI 1073613972
$6,244.82
in general payments reported to CMS, 2019-2025
72 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $377 · 2021: $528 · 2022: $1,012 · 2023: $1,048 · 2024: $1,116 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.43 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.58 | 2021-2025 | Vraylar, Qulipta, Ozurdex |
| Novo Nordisk INC | $370.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $353.04 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $344.67 | 2022-2025 | Hyqvia |
| Amgen INC. | $303.71 | 2019-2024 | Uplizna |
| Pfizer INC. | $295.31 | 2019-2025 | |
| Lundbeck LLC | $262.01 | 2021-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $246.68 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $189.04 | 2019-2025 | Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $183.63 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $156.13 | 2022 | |
| Acadia Pharmaceuticals INC | $132.40 | 2019-2024 | Nuplazid |
| Sk Life Science, INC. | $124.07 | 2022-2024 | |
| Neurelis, INC. | $118.10 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $109.68 | 2019-2022 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.